Declaration of Helsinki

The Declaration of Helsinki is the World Medical Association’s (WMA) statement of ethical principles for medical research involving human participants, first adopted in 1964 and revised repeatedly since, most recently in October 2024. It is the primary international ethical standard specifically written for physicians conducting medical research, and it functions as a professional-association policy rather than binding law: individual countries, journals, and ethics committees adopt or reference it, but the WMA itself has no enforcement power over non-members. It builds directly on the Nuremberg Code (1947) while extending it into a living, periodically revised document intended for ongoing use by practicing physician-researchers rather than a fixed historical text.

Origin and revision history

The WMA adopted the original Declaration at its 18th General Assembly in Helsinki, Finland, in June 1964, framing it explicitly as an elaboration of the Nuremberg Code for the specific context of physicians conducting clinical and non-clinical biomedical research. Unlike the Nuremberg Code, which was fixed at the moment of a war-crimes tribunal’s verdict, the Declaration was designed from the outset to be revisited. It has been substantively revised or clarified at WMA General Assemblies on the following occasions:

• 1975 — Tokyo, Japan (29th Assembly)
• 1983 — Venice, Italy (35th Assembly)
• 1989 — Hong Kong (41st Assembly)
• 1996 — Somerset West, South Africa (48th Assembly)
• 2000 — Edinburgh, Scotland (52nd Assembly) — a major restructuring
• 2002 and 2004 — Washington DC and Tokyo — notes of clarification added to the 2000 text
• 2008 — Seoul, South Korea (59th Assembly)
• 2013 — Fortaleza, Brazil (64th Assembly) — the version in force for the following decade
• 2024 — Helsinki, Finland (75th Assembly), adopted October 19, 2024, exactly sixty years after the original

The 2024 revision followed a roughly 30-month review process involving representatives from 19 countries and was adopted unanimously. Reporting on the revision describes its direction as strengthening protections for vulnerable populations, improving clinical-trial transparency, and reinforcing commitments to fairness and equity in research — consistent with the broader trajectory of every revision since 2000, each of which has tended to add specificity around informed consent, post-trial access, and ethics-committee independence rather than alter the Declaration’s core commitments.

Structure and core principles

The current Declaration is organized into five parts: a Preamble stating its purpose and scope; General Principles (a set of roughly a dozen foundational duties); a section on Risks, Burdens and Benefits; a section on Vulnerable Groups and Individuals; and Scientific Requirements and Research Protocols, which covers ethics-committee review, privacy, informed consent, and publication and dissemination of results. Its most load-bearing provisions include:

• Physician primacy and participant welfare. The Declaration states that the physician’s duty is to promote and safeguard the health, well-being, and rights of research participants, and that this duty takes precedence over the interests of science and society.
• Informed consent. Participation by individuals capable of consenting must be voluntary, following adequate disclosure of a study’s aims, methods, funding sources, potential conflicts of interest, anticipated benefits, and foreseeable risks, together with an explicit right to refuse or withdraw at any time without reprisal.
• Independent ethics review. Every research protocol must be submitted for consideration, comment, guidance, and approval to a research ethics committee before the study begins — the international-standard equivalent of what the U.S. system implements through Institutional Review Board (IRB) review under the Common Rule (45 CFR 46).
• Vulnerable populations. Research involving groups or individuals with heightened vulnerability is justified only if it is responsive to their health needs or priorities, and such groups may not be excluded from research from which they could potentially benefit without good reason.
• Placebo controls. Placebo or no-treatment control arms are permissible only where no proven intervention exists, or where compelling and scientifically sound methodological reasons justify their use to determine efficacy or safety of an intervention, and only where participants receiving placebo or no treatment are not subject to additional risk of serious or irreversible harm as a result — the ethical baseline underlying clinical equipoise and the design constraints described in CASRAI’s placebo-controlled study design entry.
• Publication ethics. Researchers, authors, sponsors, editors, and publishers all share an ethical obligation to make results publicly available, including negative and inconclusive as well as positive results, and to disclose funding sources and conflicts of interest — a provision frequently cited as an early normative basis for clinical-trial registration and results reporting.

Relationship to the Nuremberg Code and the Belmont Report

The Declaration sits between two other foundational research-ethics documents CASRAI covers, and understanding the three together clarifies what each one actually governs:

• The Nuremberg Code (1947) is the earlier, narrower document: a ten-point statement issued as part of a war-crimes tribunal’s legal judgment, with near-absolute individual consent as its central requirement. The Declaration of Helsinki adopted the Code’s emphasis on consent and risk-benefit justification but reframed it as an ongoing professional ethical statement for physicians, and departed from the Code’s near-total exclusion of subjects who cannot personally consent by permitting, under specified safeguards, consent from a legally authorized representative — a change necessary to allow ethically conducted pediatric, emergency, and incapacitated-patient research at all.
• The Belmont Report (1979) is a U.S.-specific document, produced by a national commission after the Tuskegee Syphilis Study, that distills research ethics into three principles — respect for persons, beneficence, and justice — and became the basis for the U.S. Common Rule. The Declaration of Helsinki, by contrast, is international in scope, written by and for physicians specifically (rather than researchers generally), and is periodically revised by the WMA rather than fixed as a single national policy document.

In practice, the three documents are complementary rather than competing: a physician-investigator running an international multi-site clinical trial in the United States is typically expected to satisfy the Declaration of Helsinki’s ethical principles, the Common Rule’s (or FDA’s) binding regulatory requirements traceable to Belmont, and local IRB/ethics-committee determinations, all at once.

Role in ICH Good Clinical Practice (GCP)

The Declaration of Helsinki is also the explicit ethical foundation cited by the International Council for Harmonisation’s E6 Good Clinical Practice guideline (ICH E6, now in its R2/R3 iterations), the standard that governs the design, conduct, monitoring, and reporting of industry-sponsored clinical trials worldwide. ICH E6 states that trials should be conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki, and its own foundational principles — that the rights, safety, and well-being of trial subjects are the most important considerations and should prevail over interests of science and society, and that a trial should be approved by an independent ethics committee before initiation — are the Declaration’s principles operationalized as binding requirements for regulatory drug and device trials. This is the practical route by which the Declaration’s language reaches day-to-day clinical-trial operations even in jurisdictions where the Declaration itself has no direct legal force: sponsors, CROs, and investigators comply with ICH GCP, and ICH GCP in turn incorporates the Declaration by reference.

Why it still matters to research administrators

Research administrators and IRB/ethics-committee staff encounter the Declaration of Helsinki most often indirectly — cited in a protocol’s ethics section, referenced in a sponsor’s standard operating procedures, or invoked in journal author guidelines requiring a statement that a study was conducted in accordance with it. Because it is a professional-association statement rather than law, its authority comes from near-universal voluntary adoption across the biomedical research and publishing community: most major medical journals require, as a condition of publication, a statement that human-subjects research was conducted in accordance with the Declaration of Helsinki (or an equivalent national standard), and most clinical-trial sponsors build it into protocol templates and investigator agreements by default. Knowing what the Declaration actually requires — independent ethics review, genuine informed consent, justified use of placebo, and results transparency — is what lets administrators evaluate whether a protocol’s ethics narrative is doing more than reciting the document’s name.

References

• World Medical Association, “WMA Declaration of Helsinki — Ethical Principles for Medical Research Involving Human Participants” (current text, as revised October 2024), wma.net.
• World Medical Association, “The World Medical Association General Assembly 2024 in Summary” (75th General Assembly, Helsinki, October 16-19, 2024), wma.net.
• International Council for Harmonisation, ICH Harmonised Guideline: Good Clinical Practice E6(R2)/E6(R3).
• See also CASRAI’s entries on the Nuremberg Code and the Belmont Report for the surrounding lineage of research-ethics codes.